<h4>Background</h4>Abemaciclib is approved for hormone-receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) locally advanced/metastatic breast cancer (ABC) and high-risk early BC (EBC) in China. The gene discussed is ERBB2; the disease is aneurysmal bone cyst.